Investigators were seeking clarification on optimal sequencing of the immune checkpoint inhibitor atezolizumab following ...

During a Case-Based Roundtable meeting, Lipson and participants talked about the complexity of choosing the right therapy for ...

Discover which therapies are expected to grab the PD/L-1 Market Share @ PD/L-1 Treatment Market Size ...

Final data demonstrate CM24 in combination with nivolumab and Nal-IRI/5FU/LV chemotherapy clear and consistent improvement ...

(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, 2024, was host to the Bladder Cancer Course and the session Metastatic ...

At ESMO 2024, Dr. Andrea Necchi presented the results of an interim analysis of SunRISe-4, noting a pathological complete response rate in the combination arm of 42% and pathologic objective response ...

Most of the benefit came from patients with high PD-L1 levels, where the ORR was 31 ... of LAG-3 drug relatlimab with PD-1 inhibitor nivolumab, sold on its own as Opdivo. So far, that is only ...

Patients with high PD-L1 expression account for about 40% of ... abstract from its CheckMate-9LA trial of PD-1 inhibitor Opdivo (nivolumab), CTLA4 inhibitor Yervoy (ipilimumab) plus “limited ...

Replimune's BLA submission and promising pipeline drugs are set to impact the global melanoma therapeutics market. Read more ...

今天，国家医疗保障局官网正式公布了《国家基本医疗保险、工伤保险和生育保险药品目录（2024 年）》，新一年的医保目录将于 2025 年 1 月 1 ...

DENVER (KDVR) — Denver police officers responded to areas along Federal Boulevard three times on Friday for incidents that occurred between 2 p.m. and 4 p.m. The Denver Police Department first ...

Your doctors consider many factors to help them decide about your treatment. These include: how far your cancer has grown or spread (the stage) your general health and level of fitness the type of ...